Daunorubicin
- Generic Name
- Daunorubicin
- Brand Names
- Cerubidine, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO10
- CAS Number
- 20830-81-3
- Unique Ingredient Identifier
- ZS7284E0ZP
- Background
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
- Indication
For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
Daunorubicin is indicated in combination with cytarabine for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Chronic Phase Chronic Myeloid Leukemia, Ewing's Sarcoma, Lymphoma, Diffuse, Myeloblastic Leukemia, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Wilms' tumor
Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: Steroidal Eye Drops
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 258
- Registration Number
- NCT04778397
- Locations
- 🇦🇺
Fiona Stanley Hospital, Murdoch, Western Australia, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirateProcedure: Bone Marrow BiopsyProcedure: Electrocardiography
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 32
- Registration Number
- NCT04659616
- Locations
- 🇺🇸
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia
- Conditions
- Relapsed Pediatric ALLRelapsed Pediatric AMLRefractory Acute Myeloid LeukemiaRefractory Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Children's Mercy Hospital Kansas City
- Target Recruit Count
- 1
- Registration Number
- NCT04562792
- Locations
- 🇺🇸
Children's Mercy Hospital, Kansas City, Missouri, United States
Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage
- Conditions
- Acute Leukemia of Ambiguous Lineage
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2020-06-19
- Lead Sponsor
- wang, jianxiang
- Target Recruit Count
- 50
- Registration Number
- NCT04440267
- Locations
- 🇨🇳
HBDH, Tianjin, Tianjin, China
AflacLL1901 (CHOA-AML)
- Conditions
- Acute Myeloid LeukemiaAML, Childhood
- Interventions
- Procedure: Stem cell transplantation (SCT)
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Emory University
- Target Recruit Count
- 8
- Registration Number
- NCT04326439
- Locations
- 🇺🇸
Egleston Hospital, Atlanta, Georgia, United States
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyOther: Fludeoxyglucose F-18Drug: Liposome-encapsulated Daunorubicin-CytarabineProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyOther: Questionnaire Administration
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1186
- Registration Number
- NCT04293562
- Locations
- 🇨🇦
Kingston Health Sciences Centre, Kingston, Ontario, Canada
🇺🇸Banner Children's at Desert, Mesa, Arizona, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia
- Conditions
- Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic TherapySecondary Acute Myeloid Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: Hematopoietic Cell TransplantationProcedure: Multigated Acquisition ScanProcedure: Punch Biopsy
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT04214249
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸Wake Forest Baptist Health - Wilkes Medical Center, Wilkesboro, North Carolina, United States
AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance
- Conditions
- Acute Myeloid Leukemia With FLT3/ITD Mutation
- Interventions
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2022-03-02
- Target Recruit Count
- 172
- Registration Number
- NCT04174612
- Locations
- 🇮🇹
Aou San Luigi Gonzaga - Orbassano - Scdu Ematologia Generale E Oncoematologia, Orbassano, Italy
🇮🇹Aulss 3 Serenissima, Ospedale Dell'Angelo - Mestre - Uo Ematologia, Mestre, Italy
🇮🇹Aou Policlinico P. Giaccone - Palermo - Uo Ematologia, Palermo, Italy
Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML
- Conditions
- MDSAML
- Interventions
- First Posted Date
- 2019-08-19
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- GWT-TUD GmbH
- Target Recruit Count
- 150
- Registration Number
- NCT04061239
- Locations
- 🇦🇹
Uniklinikum Salzburg - Landeskrankenhaus, Salzburg, Austria
🇩🇪Universitätsklinikum Augsburg, Augsburg, Germany
🇩🇪Klinikum Frankfurt (Oder) GmbH, Frankfurt, Germany
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
- Conditions
- Lymphoblastic Lymphoma, Childhood
- Interventions
- First Posted Date
- 2019-08-02
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 683
- Registration Number
- NCT04043494
- Locations
- 🇦🇹
Univ.Klinik für Kinder- und Jugendheilkunde Graz, Klin. Abteilung für pädiatrische Hämato-Onkologie, Graz, Austria
🇦🇹Univ.Klinik für Kinder- und Jugendheilkunde Innsbruck, Universitätsklinik für Pädiatrie I, Innsbruck, Austria
🇦🇹Kepler Universitätsklinikum, Med Campus IV / Onkologie, Linz, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.